Protalix BioTherapeutics (PLX) Reports Q4 EPS of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.59 -0.77%
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Revenue Growth %: -33.6%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of $0.02, versus ($0.04) reported last year. Revenue for the quarter came in at $3.8 million, versus $1.8 million reported last year.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- Piper Sandler Companies (PIPR) Misses Q3 EPS by 6c, Misses on Revenue
- Oracle shares drop on AI spending concerns and Microsoft criticism
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
